Oral Curcumin for the Treatment of Pain of Thumb Base Joint (CMC) Arthritis

Exclusion Criteria

• •1. Participant does not speak English.
• •2. Participant is blind.
• •3. Severe cardiac, pulmonary, liver, gastrointestinal and hematological disease (including coagulopathy), and /or renal disease.
• •4. Abnormal hematological, coagulation, and/or liver function test results.
• •5. Coumadin use at time of screening.
• •6. Use of any anticoagulant and antiplatelet medication.
• •7. History of mental illness.
• •8. Participant who is incarcerated.
• •9. History of drug or substance abuse.
• •10. Pre-existing curcumin or turmeric product usage within 3 months of the study period.
• •11. Participant has had a corticosteroid injection ≤ 60 days prior.
• •12. Participant has had prior surgery for osteoarthritis treatment
• •13. Participant who has fibromyalgia and post-operative pain.
• •14. Females who are pregnant, nursing or planning a pregnancy
• •15. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP3A4:
• •* Itraconazole,
• •* Ketoconazole,
• •* Azamulin,
• •* Troleandomycin,
• •* Verapamil,
• •* John's wart,
• •* Phenobarbital,
• •16. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP2C19:
• •* Nootkatone,
• •* Ticlopidine,
• •* Rifampin,
• •* Omeprazole),
• •17. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP2C8:
• •* Montelukast,
• •* Quercetin,
• •* Phenelzine,
• •* Rifampin,
• •* Clopidogrel ,
• •18. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP2C9:
• •* Sulfaphenazole,
• •* Tienilic acid,
• •* Carbamazepine,
• •* Apoflutamide ,
• •* Fluconazole,
• •* Celecoxib,
• •19. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP1A2:
• •* alpha-Naphthoflavone,
• •* Furafylline,
• •* Phenytoin,
• •* Rifampin,
• •* Ritonavir,
• •* smoking,
• •* Teriflunomide,
• •* Ciprofloxacin,
• •* oral contraceptives,
• •* Allopurinol
• •20. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP2B6 :
• •* Sertraline,
• •* Phencyclidine,
• •* Thiotepa,
• •* Ticlopidine,
• •* Carbamazepine,
• •* Efavirenz,
• •* Rifampin,
• •* Bupropion)